{
  "id": 8325701,
  "title": "Pan-B-Lineage Targeting with Adapter CAR-T Cells Controls Antigen-Heterogeneous Lymphoma",
  "url": "https://urgent.news/2026/09/18/pan-b-lineage-targeting-with-adapter-car-t-cells-controls-antigen",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-18T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.12.751171v1?rss=1"
  },
  "original_language": "en",
  "account": "In a significant breakthrough for B-lineage malignancies, researchers have developed a novel approach called Adapter CAR-T cells (AdCAR-T) to overcome the challenges posed by antigen heterogeneity and antigen-negative relapse. This research builds upon the previously successful AdCAR-T platform that allowed for the redirection of engineered T cells to various surface antigens using biotinylated adapter molecules (AMs).\n\nThe study showcased the effectiveness of generating AMs from three different sources: an in-house-produced tafasitamab biosimilar targeting CD19, commercial rituximab targeting CD20, and an in-house-produced daratumumab biosimilar targeting CD38. These AMs demonstrated potent, antigen-specific cytotoxicity when used individually. However, the researchers found that when simultaneously targeting CD19, CD20, and CD38, it effectively controlled a defined heterogeneous Burkitt lymphoma model in vitro and induced sustained tumor control in vivo.\n\nThe key advantage of this pan-B-lineage strategy lies in its ability to select for antigen-negative tumor populations while preventing the development of antigen-negative relapse. The researchers observed selective loss of the CD38+ AdCAR-T cell population after exposure to CD38-directed AMs, a phenomenon known as fratricide. Despite this, the surviving CD38low population retained its cytotoxic activity, ensuring the overall effectiveness of the treatment.\n\nThese findings pave the way for the development of antibody-derived AM combinations tailored for B-cell malignancies, offering a promising pan-B-lineage approach to tackle pre-existing antigen heterogeneity in these aggressive cancers.",
  "summary": "Antigen heterogeneity and antigen-negative relapse represent major limitations to durable CAR-T cell efficacy in B-lineage malignancies. We previously developed the Adapter CAR-T cell (AdCAR-T) platform, which enables flexible redirection of engineered T cells to distinct surface antigens through biotinylated adapter molecules (AMs). In this study, AMs generated from an in-house-produced…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}